Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 49Carcinoma, Renal Cell 30Neoplasm Metastasis 18Neoplasms 15Kidney Neoplasms 14Neuroendocrine Tumors 11Carcinoma, Neuroendocrine 9Prostatic Neoplasms 7Melanoma 7Triple Negative Breast Neoplasms 6Thyroid Neoplasms 6Sarcoma 6Meningioma 6Lymphoma 6Glioma 6Endometrial Neoplasms 6Tuberous Sclerosis 5Stomach Neoplasms 5Recurrence 5Lymphoma, Mantle-Cell 5Head and Neck Neoplasms 5Colorectal Neoplasms 5Carcinoma, Hepatocellular 5Carcinoma 5Pancreatic Neoplasms 4Ovarian Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Liver Neoplasms 4Carcinoma, Islet Cell 4Astrocytoma 4

Interventions

pyrotinib 3exemestane 3Trastuzumab 3Letrozole 3Anastrozole 3Drug Evaluation 2Docetaxel 2Aromatase Inhibitors 2figitumumab 1dalpiciclib 1Zoledronic Acid 1Vinorelbine 1Trabectedin 1Tamoxifen 1Lapatinib 1Everolimus 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Breast Diseases × Everolimus × Clear all
NCT01499160 2022-02-11

Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer

University of Maryland, Baltimore

Phase 2 Terminated
7 enrolled 6 charts
Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡